Company Active PRIVATE-LIMITED-GUARANT-NSC

Company profile

Centre For Process Innovation Limited

Let's innovate together | CPI

CPI is an innovation catalyst for the adoption of advanced tech and manufacturing solutions that benefit people, places, and our planet.

CRN
05002194
Founded
2003
Age
22

Overview

Legal name
CENTRE FOR PROCESS INNOVATION LIMITED
Region
North East England
Registered address
WILTON CENTRE
WILTON
REDCAR
CLEVELAND
TS10 4RF
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Centre For Process Innovation Limited
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

8 events
06 Jan
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

23 Dec
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

28 Oct
2024

Accounts With Accounts Type Group

Accounts PDF pending

AA | Transaction MzQ0MTA5OTYyNGFkaXF6a2N4 | Paper/PDF filed

Published 30 Oct 2024 07:17

01 Oct
2024

Appoint Person Secretary Company With Name Date

Officers

AP03 | Transaction MzQzNzkxMzg5MGFkaXF6a2N4

Published 01 Oct 2024 07:33

30 Sep
2024

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzQzNzY3NDY4NmFkaXF6a2N4

Published 30 Sep 2024 07:49

23 Dec
2003

Incorporated

Inception

Company registered at Companies House

Public funding

233 awards
First funded
2006
Funded years
2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026
Age at first award
2 years

Projects

2026 Grant for R&D

Enhancing Enzyme Quality and Yield to Unlock Sustainable Biocatalytic Nitration

1 Feb 2026 to 31 Jul 2026

Awarded
£59,145
Total cost £59,145

Our project, Novel Biocatalysts for Sustainable Manufacture of Pharmaceuticals, is developing a greener, safer way to produce important pharmaceutical chemicals. Traditional chemical processes for adding nitro groups to molecules require harsh conditions and generate hazardous waste. We are replacing these methods with enzymes called nitrating cytochrome ...

2026 Grant for R&D Lead participant

Enhanced assays for low dose, high potency RNA-LNP medicines

1 Feb 2026 to 31 Jul 2026

Awarded
£52,046
Total cost £52,046

Self-amplifying RNA (saRNA) is a new class of therapeutic RNA which offers major sustainability benefits compared with conventional RNA, including higher potency and substantially reduced dose requirements. This supports greener manufacturing and lowers resource use across production, storage, and administration. However, these same properties mean that a...

2026 Grant for R&D

Advanced Medicine Manufacturing Sensor

1 Feb 2026 to 31 Jul 2026

Awarded
£36,843
Total cost £36,843

As AMM therapies become more mainstream, conventional measurement and analysis technologies are increasingly pushed beyond their traditional usage boundaries. LiquiSensor is an emerging technology with strong potential for pharmaceutical process monitoring, but its current implementation presents challenges in this new field. Personalised medicine relies ...

2026 Centres Lead participant

Verinnogen Ltd

1 Jan 2026 to 31 Mar 2026

Awarded
£500,000
Total cost £500,000
2025 Collaborative R&D Lead participant

HLA Start and Scale RTO Pilot

1 Nov 2025 to 31 Oct 2026

Awarded
£890,000
Total cost £890,000
2025 Centres

Smart Personalised Healthcare: Evaluation, Response and Engagement (SPHERE)

1 Oct 2025 to 31 Mar 2026

Awarded
£250,006
Total cost £250,006

The **S**mart **P**ersonalised **H**ealthcare: **E**valuation, **R**esponse and **E**ngagement (**SPHERE**) is a UK-wide collaboration led by the Catapult Network that aims to make personalised and preventative healthcare a practical reality for everyone. The vision: _"A healthcare system where every individual receives the right diagnosis, the right trea...

2025 Centres Lead participant

Cotton Mouton Diagnostics

1 May 2025 to 31 Oct 2025

Awarded
£500,000
Total cost £500,000
2025 Investment Accelerator

pilot Centre of Expertise for Advanced Materials and Sustainability

1 Apr 2025 to 31 Mar 2026

Awarded
£399,072
Total cost £399,072

The pilot Centre of Expertise for Advanced Materials and Sustainability (CEAMS) (formerly Sustainable Materials Translational Research Centre (SMTRC)) is a collaboration funded by the Innovation Accelerator (IA) programme (2023-2025) via Greater Manchester Combined Authority (GMCA) and Innovate UK (IUK). It is led by major regional and national stakeholde...

2025 Collaborative R&D

Novel Biocatalysts for Sustainable Manufacture of Pharmaceuticals

1 Mar 2025 to 28 Feb 2027

Awarded
£265,504
Total cost £265,504

ErebaGen harnesses chemistry from Nature and its project aims to transform hazardous chemical manufacture through the use of sustainable biological processes. The innovation focus and need is aromatic nitration, a critical chemical step in production of numerous pharmaceutical intermediates. This reaction proceeds rapidly, generates heat, can get out of c...

2025 Collaborative R&D

Bioprocess development for sustainable production of mycosporines

1 Mar 2025 to 28 Feb 2026

Awarded
£125,476
Total cost £125,476

Traditional sunscreen formulations are highly effective for the prevention of skin cancer (the 5th most common cancer in the UK). However, the UV protective active ingredients used in their formulations have a number of health and environmental issues. Some sunscreen actives can absorb into the skin, leading to hormone disruption and skin sensitivity issu...

2025 Collaborative R&D

Antibodies Unchained: Cold-Chain Free and Patient-Friendly therapies

1 Feb 2025 to 31 Jan 2027

Awarded
£408,178
Total cost £408,178

Currently antibody medicines require ultra-cold-chain during production and storage to prevent spoiling due to aggregation at the molecular level, which can occur at any stage from factory to patient. This project uses game-changing, proprietary Ensilication technology to remove this cold-chain dependence in the manufacturing and supply of antibody treatm...

2025 Collaborative R&D

The Bio Revolution for weight-loss drugs: Enabling biomanufacturing of blockbuster GLP-1 agonists

1 Feb 2025 to 31 Jan 2027

Awarded
£346,107
Total cost £346,107

Therapeutic peptides are set to dominate the top-selling drugs list over the next decade. Incretin mimetics such as Semaglutide (brand names Ozempic/Wegovy/Rybelsus) and Tirzepatide (brand names Zepbound/Mounjaro) are projected to make up 5 of the top 10 selling drugs by 2030, with combined sales of $116Bn. Each of these active pharmaceutical ingredients ...

Product types

BEIS-Funded Programmes BIS-Funded Programmes Centres Collaborative R&D Demonstrator EU-Funded Fast Track Feasibility Studies Grant for R&D GRD Proof of Concept Investment Accelerator Knowledge Transfer Partnership Launchpad Small Business Research Initiative Special Interest Group Study